Clinical practice update provides revised guidelines for using zuranolone and brexanolone in postpartum depression, indicating improved treatment strategies.
This Clinical Practice Update provides revised guidance on the use of brexanolone and zuranolone in the postpartum period for depression that has onset in the third trimester or within 4 weeks postpartum. This document is a focused update of related content in Clinical Practice Guideline No. 5, Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum (Obstet Gynecol 2023;141:1262–88) and replaces the August 2023 Practice Advisory, Zuranolone for the Treatment of Postpartum Depression .
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: